Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CTX-712 |
Synonyms | |
Therapy Description |
CTX712 inhibits Clk, leading to decreased phosphorylation of SR proteins such as SRSF3-6 and potentially resulting in anti-tumor activity (Blood (2019) 134 (Supplement_1): 404). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CTX-712 | CTX 712|CTX712 | CTX712 inhibits Clk, leading to decreased phosphorylation of SR proteins such as SRSF3-6 and potentially resulting in anti-tumor activity (Blood (2019) 134 (Supplement_1): 404). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05732103 | Phase Ib/II | CTX-712 | A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes | Recruiting | USA | 0 |